118 related articles for article (PubMed ID: 18072516)
1. Radioimmunotherapy with radioactive nanoparticles: first results of dosimetry for vascularized and necrosed solid tumors.
Bouchat V; Nuttens VE; Lucas S; Michiels C; Masereel B; Féron O; Gallez B; Vander Borght T
Med Phys; 2007 Nov; 34(11):4504-13. PubMed ID: 18072516
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy with radioactive nanoparticles: biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area.
Bouchat V; Nuttens VE; Michiels C; Masereel B; Feron O; Gallez B; Vander Borght T; Lucas S
Med Phys; 2010 Apr; 37(4):1826-39. PubMed ID: 20443505
[TBL] [Abstract][Full Text] [Related]
3. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
[TBL] [Abstract][Full Text] [Related]
4. Experimental radioimmunotherapy.
Buchsbaum DJ; Langmuir VK; Wessels BW
Med Phys; 1993; 20(2 Pt 2):551-67. PubMed ID: 8492764
[TBL] [Abstract][Full Text] [Related]
5. Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy.
Penfold SN; Brown MP; Staudacher AH; Bezak E
Appl Radiat Isot; 2014 Aug; 90():40-5. PubMed ID: 24685493
[TBL] [Abstract][Full Text] [Related]
6. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.
Lucas S; Feron O; Gallez B; Masereel B; Michiels C; Vander Borght T
Comput Math Methods Med; 2015; 2015():284360. PubMed ID: 26136812
[TBL] [Abstract][Full Text] [Related]
7. Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles.
Nuttens VE; Wéra AC; Bouchat V; Lucas S
Appl Radiat Isot; 2008 Feb; 66(2):168-72. PubMed ID: 17913502
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of 90Y- and 131I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.
Song H; Du Y; Sgouros G; Prideaux A; Frey E; Wahl RL
J Nucl Med; 2007 Jan; 48(1):150-7. PubMed ID: 17204712
[TBL] [Abstract][Full Text] [Related]
9. A voxel-dose algorithm of heterogeneous activity distribution for Monte-Carlo simulation of radionuclide therapy dosimetry.
Lin H; Jing J; Cai J; Xu L
Cancer Biother Radiopharm; 2012 Aug; 27(6):344-52. PubMed ID: 22804457
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry of intraperitoneally administered radiolabeled antibodies.
Roeske JC; Chen GT; Brill AB
Med Phys; 1993; 20(2 Pt 2):593-600. PubMed ID: 8492768
[TBL] [Abstract][Full Text] [Related]
11. Antibody and radionuclide characteristics and the enhancement of the effectiveness of radioimmunotherapy by selective dose delivery to radiosensitive areas of tumour.
Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Bhatia J; Morris R; Begent RH
Int J Radiat Biol; 2002 May; 78(5):407-15. PubMed ID: 12020430
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional patient-specific dosimetry in radioimmunotherapy with 90Y-ibritumomab-tiuxetan.
D'Arienzo M; Cicone F; Chiacchiararelli L; Coniglio A; Delaloye AB; Scopinaro F
Cancer Biother Radiopharm; 2012 Mar; 27(2):124-33. PubMed ID: 22283680
[TBL] [Abstract][Full Text] [Related]
13. Internal microdosimetry for single cells in radioimmunotherapy of B-cell lymphoma.
Hindorf C; Emfietzoglou D; Lindén O; Kostarelos K; Strand SE
Cancer Biother Radiopharm; 2005 Apr; 20(2):224-30. PubMed ID: 15869460
[TBL] [Abstract][Full Text] [Related]
14. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L
J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
Postema EJ; Börjesson PK; Buijs WC; Roos JC; Marres HA; Boerman OC; de Bree R; Lang M; Munzert G; van Dongen GA; Oyen WJ
J Nucl Med; 2003 Oct; 44(10):1690-9. PubMed ID: 14530488
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
18. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry.
Flynn AA; Pedley RB; Green AJ; Dearling JL; El-Emir E; Boxer GM; Boden R; Begent RH
Radiat Res; 2003 Feb; 159(2):182-9. PubMed ID: 12537523
[TBL] [Abstract][Full Text] [Related]
19. Multicellular dosimetry for beta-emitting radionuclides: autoradiography, thermoluminescent dosimetry and three-dimensional dose calculations.
Yorke ED; Williams LE; Demidecki AJ; Heidorn DB; Roberson PL; Wessels BW
Med Phys; 1993; 20(2 Pt 2):543-50. PubMed ID: 8492763
[TBL] [Abstract][Full Text] [Related]
20. Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.
Leichner PK; Kwok CS
Med Phys; 1993; 20(2 Pt 2):529-34. PubMed ID: 8492761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
